Drugs in Dev.
Pulmonary/Respiratory Diseases
Discovery Platform
United Kingdom 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Discovery Platform
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration
Details : This is the third novel target from the collaboration that has been identified using the Benevolent Platform™ across two disease areas, IPF and chronic kidney disease, and subsequently validated and selected for portfolio entry by AstraZeneca.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 17, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Discovery Platform
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Discovery Platform
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The innovative collaboration structure scientists and technologists from the two companies working side-by-side, combining the Benevolent Platform™ — an AI-driven drug discovery platform and biomedical knowledge graph with AstraZeneca’s scientific ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 15, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Discovery Platform
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration
